Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGAcell
- Development stage
- Preclinical
- Lead developer
- Ideeea Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intradermal
01
Overview
**AGAcell** is a preclinical intradermal allogeneic mesenchymal stem-cell therapy candidate sponsored by Ideeea Therapeutics for androgenetic alopecia. The formulation contains GMP-grade allogeneic mesenchymal stem cells with ATP and is intended to modulate the dihydrotestosterone-androgen receptor axis while improving the follicular microenvironment through effects on oxidative stress, inflammation, and vascularization. Farmalíder lists preclinical safety studies for 2025–2026 and a planned Phase I study in 2026–2027. ([farmalider.com](https://farmalider.com/wp-content/uploads/2025/11/PAGS-tript-agacell_v4-LV.pdf))
- Brand names
- AGAcell
Beyond the preview
Go deeper on AGAcell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGAcell.